Lloyd Wright {dot} org

by Stuart Lindsey, PharmD.

When an insider breaks ranks with pharmaceutical orthodoxy, it is time to take notice. "Whistleblower" may be an overused term, but the article that follows might be well worth readers' consideration before standing in line for their next prescription refill. - Andrew W. Saul, OMNS Editor

by Steve Hickey, PhD and Hilary Roberts, PhD

(OMNS, Dec 7, 2011) Evidence-based medicine (EBM) is the practice of treating individual patients based on the outcomes of huge medical trials. It is, currently, the self-proclaimed gold standard for medical decision-making, and yet it is increasingly unpopular with clinicians. Their reservations reflect an intuitive understanding that something is wrong with its methodology. They are right to think this, for EBM breaks the laws of so many disciplines that it should not even be considered scientific. Indeed, from the viewpoint of a rational patient, the whole edifice is crumbling.

CAMBRIDGE, Mass. (TheStreet) --U.S. regulators on Monday approved Incivek, a new hepatitis C drug from Vertex Pharmaceuticals (VRTX).

And now, Vertex's executives and employees can breathe a sigh of relief and get to work marketing Incivek against its main hepatitis C rival Merck.

Not that Incivek's U.S. approval was ever in doubt, but the level of anxiety at Vertex must have been a tad high given that Merck received U.S. Food and Drug Administration approval for its Hep C drug Victrelis on May 13, followed by a recommendation for European approval last Friday.

This came in from the Ask Lloyd form the other day

Scientists in San Antonio, Texas say that they have been able to develop a new milestone drug which can help in the combat against the liver-ravaging Hepatitis C virus. KENS' Wendy Rigby reports.

Hepatitis C is Big Business for Pharmaceutical Companies.

GlobalData’s analysis suggests that the global hepatitis C market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the hepatitis C market.

Dear Lloyd,

I have been your loyal "patient" with Hepatitis "disease" and find your "medical" routine highly effective.

In fact, I am living symptom free and consider myself "cured."   I am so grateful to have found you - your records may show that I bought a number of products from you years ago.   Your lifestyle advice works for a variety of illnesses - including the common cold. It has changed my life and the life of my children. I am an attorney and have four degrees, and I agree with you that the FDA, WHO, etc have an agenda.   We have to try to keep rising above it.

Rockville-based Human Genome Sciences said Monday that it doubts that federal regulators will approve its treatment for chronic hepatitis C after the drug received an unfavorable preliminary review from the Food and Drug Administration.

From: Danny
Sent: Wednesday, June 09, 2010 7:10 AM
To: lloyd
Subject: Need Advice

Dear Lloyd,

As you know I am on your program.